# Citigroup (C) — Financial Analysis

**Exchange:**   
**Coverage as of:** 2026-Q2  
**Updated:** 2026-06-04  
**Tier:** Free primer (step 2 of 19)  
**Sibling pages:** /stocks/C/thesis · /stocks/C/memo

## Financial Snapshot

---
source: coverage-next-full
step: 04
ticker: C
created: 2026-06-03
---

### Step 04 — Financial Quality: Citigroup Inc. (C)

#### 1. Income Statement Quality

##### Revenue Trend (Net Revenues)
| Year | Net Revenue | YoY Growth | Notes |
|------|------------|-----------|-------|
| FY2020 | $74.3B | flat | COVID / low rate impact |
| FY2021 | $71.9B | -3.2% | IB normalization; consumer recovery |
| FY2022 | $75.3B | +4.7% | Rate benefit on NII |
| FY2023 | $78.5B | +4.3% | Continued rate benefit; divestiture costs |
| FY2024 | $81.1B | +3.3% | TTS growth; USPB strength; expense discipline |
| FY2025A | $85.2B | +5.1% | Transformation gains, IB recovery |
| FY2026E | $93.5B | +9.7%E | Further inflection + Markets |

Revenue quality is medium-high: TTS and Securities Services fees are recurring and sticky [Fact, S2]. Markets revenue is volatile but trend-positive. USPB revenue is real but elevated by elevated card balances (which also bring higher credit losses) [Fact, S1].

##### Net Income Trend
| Year | Net Income | EPS (diluted) | Key Explanation |
|------|-----------|--------------|----------------|
| FY2022 | $14.8B | $7.00 | Elevated NII from rate hikes |
| FY2023 | $9.2B | $4.36 | Repositioning charges ($4.2B); Argentina CTA loss |
| FY2024 | $12.7B | $5.94 | +37%; normalization + Transformation gains |
| FY2025A | ~$16.1B adj. | ~$7.53 adj. | Further improvement |
| Q1 2026 | — | $3.06 (+16% vs est.) | Decade-best quarter |

**FY2023 trough explanation:** ~$4.2B in pretax repositioning charges (severance, reorganization), plus a $1.7B Argentina currency translation adjustment loss. These were one-time; the underlying franchise was materially better than GAAP suggests [Fact, S2].

#### 2. Statement Quality Adjustments

##### Adjustments for Analytical Purposes
1. **Repositioning charges (FY2023):** Add back ~$4.2B pretax / ~$3.1B after-tax. Normalized FY2023 NI ≈ $12.3B, normalized EPS ≈ $5.80 [Fact, S2]
2. **Argentina CTA loss (FY2023):** Non-recurring translation item; add back ~$880M after-tax for analytical comparability [Fact, S2]
3. **FDIC special assessment (FY2023):** ~$1.0B — one-time industry-wide assessment; add back for comparability [Fact, S2]
4. **Banamex wind-down costs:** Various charges related to separating Mexico consumer business; add back for ongoing operations comparison [Estimate]
5. **Legacy civil money penalties:** $400M (2020 OCC consent order), $60.6M (2024 Fed), $75M (2024 OCC addenda). These are non-recurring compliance costs [Fact, S4]

Adjusted FY2024 earnings basis aligns closely with GAAP ($12.7B). FY2025 adjusted NI $16.1B is the key stepping-stone to FY2026 consensus.

#### 3. Balance Sheet Quality

##### Capital Fortress Assessment
| Metric | FY2024 | Requirement | Buffer |
|--------|--------|-------------|--------|
| CET1 Ratio | 13.63% | 12.1% | +153bps |
| Tier 1 Capital Ratio | 15.1% | ~13.5% | +160bps |
| Total Capital Ratio | 17.4% | ~15.5% | +190bps |
| Supplementary Leverage (SLR) | ~6.0%+ | 5.0% | ~100bps |

CET1 at 13.63% is among the highest for U.S. G-SIBs. This reflects both Transformation discipline (reducing RWA in low-return businesses) and profitable retained earnings. The excess capital ($15-25B above operational minimum) supports the $30B buyback authorization [S1][S5].

##### Asset Quality
| Metric | FY2024 | FY2023 | Trend |
|--------|--------|--------|-------|
| Provision for Credit Losses | ~$9.3B | ~$9.2B | Stable elevated |
| USPB Net Charge-Off Rate | ~5.0-5.5% | ~3.8% | Rising (normalizing from COVID-era lows) |
| Total NCOs (USPB) | $7.6B | $5.2B | +45% YoY [S2] |
| Institutional Credit Losses | Minimal | Minimal | Stable |

**Critical observation:** USPB credit losses are the primary earnings headwind. The NCO rate rising from historically low COVID-era levels to 5%+ reflects normalization (not a credit crisis). Industry credit card NCO rates broadly rose 2022-2024 [Fact, S6]. Citi's USPB has higher-risk card segments than, e.g., American Express. Management guides for NCO stabilization in 2025-2026 [A3].

##### Liquidity
$1.284T in deposits provides a stable, low-cost funding base [S1]. Citi's liquidity coverage ratio (LCR) and net stable funding ratio (NSFR) are comfortably above 100%. No near-term wholesale funding cliff.

#### 4. Adversarial Research Sweep

##### Short Reports / Notable Criticisms
*Note: No transcript analysis. Sources: filings, press releases, analyst research, news search.*

**1. Consent Order Overhang (Active Regulatory Risk)**
The OCC (2020) and Fed (2024) consent orders require Citi to remediate data governance, risk management infrastructure, and controls. As of early 2026, >80% of programs are at or near target state, and OCC removed one amendment in December 2025. However, full consent order closure is not certain by 2026. If orders persist into 2027-2028, Citi's ability to make certain acquisitions, engage in certain capital-market activities, and attract top talent is constrained [Fact, S4][S5].

**2. ROTCE Timeline Push (Credibility Risk)**
Citi's original 11-12% ROTCE target was for 2025. It was subsequently pushed to 2026 (>10%), then to 2027-28 (11-13%), and the long-term 14-15% target is now for 2029-31. Each push has eroded management credibility on timeline. Bears cite this "guidance creep" as a reason to discount future commitments [Fact, S7].

**3. USPB Credit Quality (Structural or Cyclical?)**
Bulls argue NCO normalization is cyclical (COVID-era suppressed defaults now reverting to mean). Bears argue Citi's card book is structurally higher-risk than peers (higher subprime/near-prime mix), and that NCO rates will remain structurally elevated vs. pre-2020 levels. Citi does not disclose FICO distribution as granularly as Capital One — this ambiguity is a bear point [Judgment, S6].

**4. CFRA Downgrade (May 2026)**
CFRA downgraded Citi to Hold (from Buy) in May 2026 citing stretched valuations post-Q1 beat and Investor Day rally. P/TBV at 1.25x already reflects much of the ROTCE improvement. CFRA argued the remaining upside requires ROTCE execution by 2028-2031 — a long hold period [Fact, S7].

**5. Jane Fraser Dual Role (Governance)**
Jane Fraser became both CEO and Board Chair in October 2025. This combined role is atypical for U.S. banks and a governance risk. Say-on-pay dropped from 91% (2025) to 60% (2026) after a controversial $25M equity award tied to her assuming the Chair role. Institutional Shareholder Services (ISS) and Glass Lewis opposed [Fact, S4].

**6. No Active Short Campaign Found**
No prominent short sellers have published bearish reports on Citigroup. The investment case is debated within sell-side research, not by activist shorts. This reduces the risk of a documented short thesis that the market doesn't already know.

##### Litigation / Legal (Key Items from 10-K)
- OCC Civil Money Penalty ($400M, 2020): ongoing consent order
- Federal Reserve Consent Order (2024, $60.6M)
- OCC Addendum (2024, $75M)
- Various class action securities litigation (routine for G-SIBs)
- MF Global trustee litigation (historical; substantially resolved)
- No active material fraud allegations in recent filings [Fact, S2]

#### 5. Financial Quality Summary

| Dimension | Assessment |
|-----------|-----------|
| Revenue quality | Medium-high (TTS/fees strong; trading volatile) |
| Earnings quality | Medium (improving; FY2023 distorted by one-time charges) |
| Balance sheet | Strong (CET1 fortress; $1.28T deposit base) |
| Credit quality | Challenged near-term (USPB NCOs elevated) but not crisis-level |
| Capital return | Very strong ($30B buyback; 1.83% dividend) |
| Regulatory/legal | Elevated risk (consent orders); declining trajectory |
| Accounting conservatism | Adequate; no red flags in GAAP presentation |

#### 6. Source Index

| Citation | Source |
|----------|--------|
| [S1] | SEC XBRL company facts (capital ratios, balance sheet) |
| [S2] | SEC 10-K FY2024 — NCO data, repositioning charges, legal |
| [S4] | SEC DEF 14A proxy — governance, executive compensation |
| [S5] | Investor presentations — ROTCE trajectory, consent order updates |
| [S6] | Industry research — card NCO cycles, CFRA downgrade context |
| [S7] | Consensus + recent news — analyst views, Q1 2026 beat |

## Deeper Financial Analysis

The fundamental tier ($1.00) adds 8 dimensions not included here:

- Revenue Breakdown — segment revenue, geographic mix, product-line margins
- Financial Trends — QoQ momentum, leading indicators, inflection points
- Balance Sheet — debt structure, dilution risk, working capital dynamics
- Capital Allocation — ROIC, buyback cadence, reinvestment efficiency
- Earnings Analysis — beats/misses, guidance vs actuals, transcript highlights
- Competitive Positioning — market share, pricing power, peer benchmarks
- Industry Context — TAM, sector tailwinds/headwinds, regulatory backdrop

**API endpoint:** GET /api/v1/research/C/fundamental

## Navigation

- Overview: /stocks/C
- Financials (this page): /stocks/C/financials
- Thesis: /stocks/C/thesis
- Investment Memo: /stocks/C/memo
- Coverage universe: /stocks